마시모(MASI) 주가 전망 및 기업 분석 - PER·배당·실적·목표주가·RSI·MACD

🏛️

거래 정지 중인 종목 2026-07-17 이후 거래가 정지되었습니다. 재개될 수 있으며, 표시된 시세는 마지막 거래일 기준입니다.

MASI

Masimo Corp

6월 9일 4:00 PM ET (한국 6/10 05:00)

$179.95

+0.00 +0.00%

마시모(MASI) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시가총액

$9.4B

스몰캡

P/E

123.4

고평가 구간

배당수익률

없음

52주 위치

100%

저점 +43% · 고점 -0%

애널리스트

보유

Fundamental health

vs. Medical Devices

수익성

Top 17%

성장

Top 52%

밸류에이션

Top 17%

재무 안정

Top 45%

Index ⓘ	-	P/E ⓘ	123.41	EPS (ttm) ⓘ	1.46	Insider Own ⓘ	2.94%	Shs Outstand ⓘ	52.4M	Perf Week ⓘ	-
Market Cap ⓘ	9.42B	Forward P/E ⓘ	26.9	EPS next Y ⓘ	10.76%	Insider Trans ⓘ	-1.2%	Shs Float ⓘ	50.8M	Perf Month ⓘ	0.64%
Enterprise Value ⓘ	9.79B	PEG ⓘ	-	EPS next Q ⓘ	-	Inst Own ⓘ	94.61%	Short Float ⓘ	6.89%	Perf Quarter ⓘ	2.2%
Income ⓘ	0.08B	P/S ⓘ	6.05	EPS this Y ⓘ	57.7%	Inst Trans ⓘ	-	Short Ratio ⓘ	3.08	Perf Half Y ⓘ	30.97%
Sales ⓘ	1.56B	P/B ⓘ	11.95	EPS next 5Y ⓘ	-	ROA ⓘ	11.02%	Short Interest ⓘ	3.50M	Perf YTD ⓘ	38.36%
Book/sh ⓘ	15.06	P/C ⓘ	75.63	EPS past 3/5Y ⓘ	-	ROE ⓘ	24.99%	52W High ⓘ	-0.02% ($179.99)	Perf Year ⓘ	4.7%
Cash/sh ⓘ	2.38	P/FCF ⓘ	44.68	Sales past 3/5Y ⓘ	-9.14% 5.95%	ROIC ⓘ	5.99%	52W Low ⓘ	42.89% ($125.94)	Perf 3Y ⓘ	15.1%
Dividend Est. ⓘ	-	EV/EBITDA ⓘ	28.14	EPS Y/Y TTM ⓘ	116.03%	Gross Margin ⓘ	61.73%	Volatility(W/M) ⓘ	0.09% 0.16%	Perf 5Y ⓘ	-15.37%
Dividend TTM ⓘ	-	EV/Sales ⓘ	6.28	Sales Y/Y TTM ⓘ	-21.03%	Oper. Margin ⓘ	19.86%	ATR (14) ⓘ	0.39	Perf 10Y ⓘ	243.29%
Dividend Ex-Date ⓘ	2012/11/23	Quick Ratio ⓘ	1.45	EPS Q/Q ⓘ	133.86%	Profit Margin ⓘ	4.84%	RSI (14) ⓘ	74.83	Recom ⓘ	3
Dividend Gr. 3/5Y ⓘ	-	Current Ratio ⓘ	2.68	Sales Q/Q ⓘ	8.49%	SMA20 ⓘ	0.65% ($178.79)	Beta ⓘ	1.09	Target Price ⓘ	$180
Payout ⓘ	-	Debt/Eq ⓘ	0.62	Earnings ⓘ	2026/05/12	SMA50 ⓘ	0.78% ($178.56)	Rel Volume ⓘ	0	Prev Close ⓘ	$179.95
Employees ⓘ	7500	LT Debt/Eq ⓘ	0.6	EPS/Sales Surpr. ⓘ	-112.17% 1.1%	SMA200 ⓘ	15.43% ($155.9)	Avg Volume(3M) ⓘ	1.14M	Price ⓘ	$179.95
IPO ⓘ	2007/8/8	Option/Short ⓘ	Yes/No			Trades ⓘ	0	Volume ⓘ	-	Change ⓘ	-

Quarterly earnings trend Quarterly earnings data is not yet available — foreign-listed companies (ADRs) only file annual reports with the U.S., and recently listed companies may not have filed their first quarterly report.

📊 Masimo Corp (MASI) Investment Analysis

What kind of company is Masimo Corp?

마시모(MASI)

Healthcare · Medical Devices

#975 by Market Cap — Mid-Cap

A U.S. medical device company that supplies patient monitoring equipment and sensors to hospitals, including devices that measure blood oxygen saturation. Its strengths lie in its recurring revenue from disposable sensors used for each patient and its measurement technology.

Learn more about Masimo Corp →

Market Cap

$9.4B

Approx. KRW 12.9 trillion

⚖️ 3% of Samsung Electronics

Market Cap Rank975

Employees7,500people

IPO2007/08/08

Current Price$179.95 ≈ 246,531원

NASD · USA

Key Events

⏰ Upcoming events

🔔 Earnings release

The next release date has not been announced yet.

🎯 Ex-dividend date

No scheduled dividends

📜 Recent events

🔔 Earnings release 2026년 5월 12일 (화) · 장 마감 후 EPS -112.2% 매출 +1.1%

🔔 Earnings release 2026년 2월 27일 (금) · 장 시작 전 EPS -112.2% 매출 +1.1%

🎯 Ex-div 2012년 11월 23일 (금)

Is it profitable?

Solid company — profitability & finances both healthy

Strong earnings and excellent financial health

Profitability — How efficiently it makes money

Operating Margin

Profit kept from selling products and services (higher is better)

19.9%

✓ 우수

My positionTop 5%

Low range Average High range

Medical Devices Median -23.9% · Top tier

💡 일반적으로 10% 이상이면 양호, 20% 이상이면 우수

Net Margin

Share of revenue left after taxes and interest are paid

4.8%

✓ 우수

My positionTop 25%

Low range Average High range

Medical Devices Median -34.5% · Top 23%

💡 일반적으로 8% 이상이면 양호, 15% 이상이면 우수

Gross Margin

Profit after subtracting raw-material costs only (signals product competitiveness)

61.7%

✓ 양호

My positionMid-range

Low range Average High range

Medical Devices Median 54.4% · Top 37%

💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)

ROE

Annual return earned on shareholders' equity (15%+ is strong)

25.0%

✓ 우수

My positionTop 25%

Low range Average High range

Healthcare 중형주 Median -17.0% · Top 9%

💡 일반적으로 15% 이상이면 우수 (단, 부채 레버리지 효과 주의)

ROA

Annual earnings relative to total company assets

11.0%

✓ 우수

My positionTop 25%

Low range Average High range

Healthcare 중형주 Median -9.3% · Top 11%

💡 일반적으로 5% 이상이면 양호, 10% 이상이면 우수

ROIC

Return generated per dollar invested in the business

6.0%

✓ 우수

My positionTop 25%

Low range Average High range

Healthcare 중형주 Median -11.9% · Top 23%

💡 자본비용(보통 8~10%)보다 높으면 가치 창출, 15% 이상이면 우수

Financial health — Debt & liquidity burden

Debt-to-Equity (D/E)

Debt relative to equity (lower is healthier)

0.62

✓ Average

My positionMid-range

Low range Average High range

Medical Devices Median 0.39

💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)

Current Ratio

Liquid assets available to cover liabilities due within a year

2.68

✓ 양호

My positionMid-range

Low range Average High range

Medical Devices Median 2.91

💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의

Quick Ratio

Liquid assets excluding inventory, available for immediate use

1.45

✓ 양호

My positionMid-range

Low range Average High range

Medical Devices Median 2.09

💡 1.0 이상이면 안전, 0.5 미만이면 주의

* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Mixed Outlook

Positive and negative signals are mixed

애널리스트 목표가

$180.00

현재가 대비 +0.0%

💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균

예상 PER (Forward)

26.90배

💡 내년 예상 EPS 기준. 현재 PER과 비교해 이익 성장 반영 정도 확인

내년 EPS 예상 성장률

+10.8%

💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상

⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

High Earnings Volatility

Frequently misses analyst estimates

예상 상회

예상 부합

예상 하회

상회 비율

-112.2%

평균 서프라이즈

2026.05.12

하회

-112.2%

2026.02.27

하회

-112.2%

💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Average Growth

Mid-range within the industry

🔮 How much will it grow? (analyst forecasts)

This Year's EPS Outlook

Projected EPS growth rate for this year

+57.7%

양호

My positionMid-range

Low range Average High range

미분류 중형주 Median 7.3% · Top 31%

Next Year's EPS Outlook

Projected EPS growth rate for next year (analyst consensus)

+10.8%

평균

My positionMid-range

Low range Average High range

미분류 중형주 Median 15.6% · Bottom 39%

📊 How much has it grown? (actual results)

Past 5-Year Revenue

How much revenue grew over the past 5 years

+6.0%

평균

My positionMid-range

Low range Average High range

미분류 중형주 Median 9.8% · Bottom 38%

⚡ Short-term momentum

QoQ Revenue

Revenue change from the previous quarter (short-term momentum)

+8.5%

평균

My positionMid-range

Low range Average High range

미분류 중형주 Median 10.8% · Bottom 46%

* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

New to investing terms? Look it up in the financial dictionary →

Has the stock risen over the long term?

Long-term weakness — -84%p below the market

MASI -15.4% · S&P 500 +68.3%

Excess return vs. market (price-based, ex-dividends)

5-year basis

vs S&P 500

-83.7%p

Significantly behind the market

vs Health Care (XLV)

-39.9%p

Significantly behind the sector average

1-year basis

vs S&P 500

-11.3%p

behind the market

vs Health Care (XLV)

-15.0%p

behind the sector average

Rank among peers

5-year return Lower-Mid (lower 26%) Based on 11 peers

1-year return Lower-Mid (lower 28%) Based on 11 peers

Current position within 52-week range

Low (-42.9%p) High (-0.0%p)

Current price is 42.9% above the 52-week low and 0.0% below the 52-week high

Recent risk (last 103 trading days)

Max drawdown

-7.2%

Annualized volatility

47.4%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 110-day series

Price · Bollinger Bands · Ichimoku Cloud

close
BB Upper
BB Mid
BB Lower
Tenkan
Kijun
Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🟡

Current diagnosis · 2026-06-18

Squeeze — volatility contraction, breakout imminent

Band width narrowed to 1.4%. Big move may be near. Above the Ichimoku cloud (bullish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🟢

Current diagnosis · 2026-06-18

Bullish momentum holding

MACD 0.470 > Signal 0.422 in positive zone + Hist positive (+0.048). Trend in progress.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

⚠️

Current diagnosis · 2026-06-18

Overbought zone — short-term pullback possible

RSI 74.8 (above 70). Buying pressure is excessive, and profit-taking may emerge. Stoch %K is also 97.6.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Pricier than peers in its industry

Pricey on Vs. Earnings·Vs. Assets·Vs. Sales·Vs. Cash Flow

💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.

💵 Vs. Earnings Pricey

🏢 Vs. Assets Pricey

🧾 Vs. Sales Pricey

💧 Vs. Cash Flow Pricey

💵 Vs. Earnings

PER Price-to-Earnings Ratio

How expensive the price is vs. earnings — lower is cheaper

123.41x

✓ Very pricey

My positionBottom 5%

Low range Average High range

Medical Devices median 30.60x · Bottom 1% — expensive within the industry

💡 PER 15 이하 저평가, 25 이상이면 성장성 검증 필요 (적자 기업은 의미 없음)

💵 Vs. Earnings

Forward PER Forward Price-to-Earnings Ratio

PER using next year's estimated earnings — reflects growth

26.90x

✓ Fair

My positionMid-range

Low range Average High range

Medical Devices median 17.57x · Around the industry average

💡 향후 12개월 예상 EPS 기준 PER. 현재 PER보다 낮으면 이익 성장 중

🏢 Vs. Assets

PBR Price-to-Book Ratio

Price vs. the company's asset value — below 1 trades cheaper than assets

11.95x

✓ Very pricey

My positionBottom 5%

Low range Average High range

Medical Devices median 2.58x · Bottom 1% — expensive within the industry

💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)

🧾 Vs. Sales

PSR Price-to-Sales Ratio

Market cap vs. revenue — lower is cheaper relative to sales

6.05x

✓ Pricey

My positionBottom 25%

Low range Average High range

Medical Devices median 2.64x · Bottom 23% — expensive within the industry

💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)

💧 Vs. Cash Flow

EV/EBITDA Enterprise Value Multiple

Total enterprise value ÷ operating cash earnings — a benchmark for M&A

28.14x

✓ Pricey

My positionBottom 25%

Low range Average High range

Medical Devices median 14.42x · Bottom 21% — expensive within the industry

💡 EV/EBITDA 10 이하 저평가, 20 이상이면 고평가 (M&A 밸류 기준)

💧 Vs. Cash Flow

P/FCF Price-to-Free-Cash-Flow Ratio

Price vs. actual cash generation — lower means more efficient

44.68x

✓ Pricey

My positionBottom 25%

Low range Average High range

Medical Devices median 21.45x · Bottom 25% — expensive within the industry

💡 P/FCF 20 이하면 현금창출 대비 저평가 (실질 수익성 기준)

Analyst target price (reference)

$180.00 vs. current price +0.0%

* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.

As of: Recent snapshot · Peer group: Medical Devices

Who owns it?

Ownership is broadly stable

Insider modest net selling -1.2% · Short interest moderate 6.9% · Short interest fell -1.3%p over the last 89 days

📈 Recent trading flow (6 months)

🧑‍💼 Insiders (executives & directors)

-1.2%

Insiders net selling

🏦 Institutions (funds & investors)

No trading data for Institutions

💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.

👥 Holdings composition

🏦 Institutions 94.6%

Institution-led, stable structure

Healthcare 중형주 Median 89.4%

🧑‍💼 Insiders 2.9%

Typical level

Healthcare 중형주 Median 9.4%

👤 Retail investors (estimated) 2.5%

Everyone excluding institutions and insiders

Institutions Insiders Retail (est.)

📉 Short-selling metrics

Short ratio

6.9%

Moderate

Healthcare 중형주 Median 11.3%

Past 89 days 📉 -1.3%p decrease

Short interest days to cover

3.1 days

Days needed to close short positions using average trading volume

🧮 Share count

Total shares outstanding 52.4M주

Float (tradable shares) 50.8M주

* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 89 days.

ETFs holding MASI

ETFs with the highest weightings · 10 total shown

RSBA

Return Stacked Bonds & Merger Arbitrage ETF

12.48%

$53M

HEAL

Global X HealthTech ETF

5.56%

$28M

MARB

First Trust Equity Market Neutral ETF

3.80%

$19M

NTRL

First Trust Equity Market Neutral ETF

3.80%

$16M

EVNT

AltShares Event-Driven ETF

2.91%

$13M

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)

Sorted by market cap, largest first

Stock	Market Cap	PER	PBR	ROE	Dividend Yield	Change
MASI This Stock	$9.4B	123.4 ▼	11.9 ▼	24.99% ▲	-	+0.0%
LLY	$1.13T	43.1 ▼	36.2 ▼	107.64% ▲	0.58% ▼	+0.1%
JNJ	$640.9B	30.8 ▼	7.5 ▼	25.74% ▲	2.02% ▲	+1.0%
ABBV	$453.9B	126.7 ▼	-	15221.82% ▲	2.67% ▲	-0.9%
UNH	$379.3B	26.9 ▼	3.9 ▼	12.49% ▲	2.16% ▲	-0.7%
MRK	$323.0B	36.8 ▼	7.0 ▼	18.97% ▲	2.5% ▲	-0.2%
Sector Avg	-	26.1	2.7	-48.83%	1.23%	-

FAQ

What kind of company is 마시모(MASI)?

마시모(MASI) belongs to the Healthcare sector and operates in the Medical Devices industry.

What is the market cap of MASI?

The market cap of MASI is approximately $9.4B, ranking 975 within its sector.

What is the P/E ratio of MASI?

MASI has a P/E ratio of approximately 123.4x, which can be used to assess its valuation relative to the Healthcare sector average.

What is the 52-week high and low for MASI?

MASI has recorded a 52-week high of $179.99 and a low of $125.94.

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.